Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. - Wikidata - wikimedia - TriplyDB

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

http://www.wikidata.org/entity/Q37535273

about

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Current issues in chronic graft-versus-host disease.Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling.Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.Islet adaptation to obesity and insulin resistance in WNIN/GR-Ob rats.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes.CXCL10: most consistent cGVHD biomarker?Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?Biomarker Panel for Chronic Graft-Versus-Host Disease.Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery.Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.A combined biomarker and clinical panel for chronic graft versus host disease diagnosis Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Onset of human preterm and term birth is related to unique inflammatory transcriptome profiles at the maternal fetal interface.A review of late complications of allogeneic hematopoietic stem cell transplantations.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Expression and function of aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.Biomarkers in chronic graft-versus-host disease: quo vadis?Changes in protein serum levels during stem cell transplantation.Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.Biomarkers for post-transplantation outcomes.

P2860

Q28076264-3D299609-5EEE-4BC1-8134-B16B3AC68A82 Q33625948-3DDE3D9A-BAC6-4EBC-BFB5-297BBE7EFC18 Q33809599-CC430C65-D590-4D88-B6AA-4EDD25205E08 Q33917187-3FD1DD9B-C152-4972-9927-BCF72DBE1180 Q34920360-2654CA8D-5546-4832-91BB-30EFE6876828 Q35180727-38CB5300-367D-40CC-93DF-38392E588056 Q35430781-0D2F8ABB-F943-4230-B2D3-ECCC793AFFD4 Q35533376-705A3386-91D8-4ED8-8455-48754A0586F9 Q35586614-D23DB13A-18C4-492F-B38E-C9BCC7B70EDE Q36004178-A6C0EB18-9FC8-4826-9312-06EE56C2C62B Q36141399-0698281C-6049-4590-920E-DBECAE13EB18 Q37015676-42180D87-EF86-46EF-9949-C781B163155E Q37015691-0F6AE030-E3E4-43E2-9472-2E95CAABC462 Q37075990-F0D3125C-9FB8-4FFD-95EC-0FFAAE0C77BF Q37234820-CAF32B54-0048-4374-B55E-3738EE20052A Q37320319-59262242-8AC8-492E-BE9C-161205B3552B Q37522548-4F4D0460-EDA9-42ED-B22B-BD1B85F17890 Q37585022-7023019E-615F-443F-9202-30EDD446EC91 Q37587724-49F62DD3-AD85-4F0B-9FF7-062E67537686 Q37601730-23710BD4-698B-4BA0-9430-A878CF76CF69 Q38381708-2B882AB7-6C09-44C4-8968-D15BFBFBE3C3 Q38392246-17522482-1D3F-4EA4-B6F7-770A21A5C083 Q38798545-81D038B8-5CAA-4F91-91F2-BEE39463950C Q39002164-8695429D-8E65-4B9E-BF9B-698E1B2FBDA6 Q40054555-F716FBA9-B136-4E2A-9FA1-1EC536921D7A Q40115697-F588E239-0CCE-488C-AB8F-A10FE1CA36F3 Q41387926-0FFDC6F5-C2C4-493D-8051-9DDB1BE6BDAF Q42552816-FAAAFCE0-D5DD-476F-B4AD-77B017E1C569 Q42737499-87F5D8DD-F319-40A5-9E8C-3FE92854365E Q47713449-7AFA0DDC-8B1B-4E13-9836-E107A857B7C6 Q47969259-BFD0A8BC-C0CF-4311-88C6-8EC46789568B Q49645938-947716ED-0446-460F-B808-A679958999E1 Q51028682-8554F990-EA1D-4021-990A-35080D2B2EA7 Q52603913-9B1E206C-9828-4C2F-BED0-41A246F123ED

P2860

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

http://www.wikidata.org/entity/Q37535273

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@en

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@nl

type

label

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@en

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@nl

prefLabel

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@en

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

@nl

P1433

Q37535273-B6C0BC48-424E-4464-B0A4-6918AF27200A

P1476

Q37535273-A3E6CEBA-EBCD-4F58-B8AC-481D8363D55F

P2093

Q37535273-2E0DD25C-A60E-4307-B37B-E6B4761A98E0

Q37535273-2E1040AE-0C2B-4092-9ECB-5A425194D21E

Q37535273-2E4FA5FC-8891-4964-B5B1-CE30931DD686

Q37535273-3D77B0CA-C25A-4F5F-9FD7-32267D41A505

Q37535273-45D6D5F9-7943-48CB-8D4D-92126B780265

Q37535273-4746876D-505C-4305-8831-26785C8658D2

Q37535273-55C960FD-517F-4CDA-914A-19EE35D29314

Q37535273-60F6A253-03CE-473C-BA17-E5061BEF063E

Q37535273-6A8EB0FD-64EF-405A-ABC3-74428C9406B1

Q37535273-86381B4D-6C32-4185-99FC-407FD26231AF

P2860

Q37535273-1287B518-E99B-42CC-8F2C-1541AAE99FA7

Q37535273-1657F525-98E0-4E06-8F19-630C8451B0C6

Q37535273-183B7FF8-D03A-4B87-917E-C8756E0A849B

Q37535273-2AC7643E-1D10-46FC-9F97-964395BEB571

Q37535273-3E3D0D5C-31DC-45C4-B79C-69868D77DC0A

Q37535273-52047990-9966-4D42-9511-245088B1BD38

Q37535273-54367CAD-54EB-488F-A576-2577CD1B42D0

Q37535273-54D5F3F9-E72A-4E1A-9108-155943B00470

Q37535273-645D5ED6-2880-41EB-A00C-BDDEBAA68444

Q37535273-6FB69944-CFCE-4B3B-A55B-810FA2E9FFCE

P304

Q37535273-D1E6E6A7-EC7C-44D0-A2C5-034504EF2FCA

P31

Q37535273-884D9FF1-3CCF-4CC0-A5AF-0F4A8B69DA9A

P356

Q37535273-030ADD2C-3065-484B-A67C-97BCD77DA787

P407

Q37535273-44843C74-FD13-48E2-A5D8-752C523498E1

P433

Q37535273-B7688B2C-1A99-408C-BA15-3F50A7DA1962

P478

Q37535273-A2F6F2D8-671F-4F2F-91D1-BF0469593526

P50

Q37535273-82B1B8C8-54CB-4DC6-926B-9DE98132B3E2

Q37535273-D18D13BE-EED6-4CE6-9162-72F565E9005B

P577

Q37535273-657A9224-EDDC-465A-A681-009870A6420A

P698

Q37535273-F269C655-380F-436C-AAE3-B68A27DF27BD

P921

Q37535273-9cbaebe3-f4f5-4c10-9578-70b4cd4879c0

P932

Q37535273-16CEF3C7-5608-41A3-A15D-1D5286D09B20

P356

BLOOD-2013-08-520072

P1433

P1476

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis

@en

P2093

Barry E Storer

http://www.w3.org/2001/XMLSchema#string

Bryan J Fiema

http://www.w3.org/2001/XMLSchema#string

Carrie L Kitko

http://www.w3.org/2001/XMLSchema#string

Daniel R Couriel

http://www.w3.org/2001/XMLSchema#string

David A Fox

http://www.w3.org/2001/XMLSchema#string

James L M Ferrara

http://www.w3.org/2001/XMLSchema#string

John A Hansen

http://www.w3.org/2001/XMLSchema#string

Kelly Lamiman

http://www.w3.org/2001/XMLSchema#string

Lawrence Chang

http://www.w3.org/2001/XMLSchema#string

Mary E Flowers

http://www.w3.org/2001/XMLSchema#string

P2860

Elafin is a biomarker of graft-versus-host disease of the skin

Advances in predicting acute GVHD

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

Clinical benefit of response in chronic graft-versus-host disease

P304

786-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-520072

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Paczesny

P577

2013-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24363401

http://www.w3.org/2001/XMLSchema#string

P921

P932

3907763

http://www.w3.org/2001/XMLSchema#string